



Numinus

At the forefront of addressing
the universal desire to heal.

Investor presentation
December 2019

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company's facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.



We address the universal desire to heal.

Numinus is an operating company at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater wellness.

Our unique growth platform includes a testing and processing facility that can leverage the emerging market of psychedelic therapies to treat mental illness, addictions and PTSD, as well as an established and fully integrated treatment and healing centre model we will scale nationally.

Sustainable cannabis revenue through our laboratory and processing facility will help fund our growth plans.

Numinus was created from the merger of Salvation Botanicals and Numinus Healing Centre and will go public via an RTO with Rojo Resources by Q1 2020.

We are one of the first companies licensed to test, sell and deliver psychedelic therapies.

Psychedelic therapies have been designated *breakthrough therapy** status by the FDA in treatment and we are on top of the next wave in addressing a growing trend of mental health issues in Canada and around the world.

First-mover advantage: Numinus was issued a dealer's licence under the Controlled Substances Act in July 2019. We will play an important role in the areas of psychedelic substances research and testing.

We can test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. We are amending our licence to soon include MDMA production.

*U.S Food and Drug Administration (FDA) designation that expedites the development and review of drugs intended to treat a serious condition

Transformative change is needed

There are epidemic rates of addiction, mental illness and physical ill health. Despite climbing patient costs, the conventional healthcare framework has made limited impact.



\$51B

Estimated annual economic burden of mental illness in Canada

1 in 2

The number of Canadians who will be affected by mental health issues by the age of 40

4,000

The number of Canadians who die by suicide per year – almost 11 suicides per day

9%+

Percentage of Canadian adults who will suffer PTSD in their lifetime

500,000

Number of unemployed Canadians who are unable to work due to mental health problems

1 in 5

The number of Canadians who suffer from addiction in any given year

50%

Percentage of Canadians experiencing a major depressive episode who do not receive “potentially adequate care”

#4

Canada’s rank in the use of antidepressant drugs per capita. The use of antidepressants is on the rise globally.

The use of psychedelics and transformative medicine in a safe, controlled, therapeutic environment is moving to the mainstream.



- [Decriminalization](#) of psilocybin in Denver and Oakland and similar legislation being discussed in Portland.
- FDA grants breakthrough therapy designation to [COMPASS PATHWAYS](#) for psilocybin-assisted therapy for treatment-resistant depression.
- FDA grants breakthrough therapy designation to [MAPS](#) for MDMA-assisted psychotherapy for the treatment of PTSD.
- [BC Centre on Substance Use](#) commencing Phase III clinical trials of MDMA for patients suffering from PTSD.
- FDA grants breakthrough therapy designation to [Usona Institute's](#) psilocybin program in the treatment of major depressive disorder.
- [Johns Hopkins](#) opening a new US\$17 MM center for psychedelic research.


Our addressable market

1. The growing number of those suffering from PTSD, addictions and mental health issues underserved by today's therapeutic model.
2. And, everyone who desires improved well-being by taking advantage of the wide range of therapeutic services offered at our Numinus Healing Centres.



We are in-market and fully integrated –
from lab facility through to healing centre
– to serve psychedelic therapy space.






Testing & processing laboratory

- 7,000 sq. ft. fully built and paid for testing and processing laboratory.
- Our license allows us to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Licence to be amended to include MDMA production.
- Meets FDA Stage 3 requirements for supplying MDMA and psilocybin trials.
- Agreement with scientists at Canadian university with patented process for producing MDMA and psilocybin products for growing number of clinical/research trials.
- Staffed by internationally-acclaimed PhDs with backgrounds in peer-reviewed research, pharmaceutical manufacturing, and advanced analytical technologies.
- Utilizing proprietary technology and chromatography, spectroscopy, and mass spectrometry techniques.


Numinus Healing Centre

- Acquired an operational facility aligned with our model that embraces evidence-based use of psychedelic therapies.
- Professional therapists and integrative health professionals guide people in the use of psychedelics, supportive therapies and sophisticated technologies to help them heal, connect and grow — in a safe, controlled therapeutic environment.
- We developed proprietary protocols, and partnered with researchers, to advance ketamine-assisted therapy in a study-setting as a treatment for depression.



Numinus Healing Centre

- The full suite of therapeutic services under one facility.
- Our unique, integrated therapeutic model creates lifelong relationships with people wanting lasting physical, mental and emotional health.
- First healing centre, located in Vancouver, includes: 6 treatment rooms, event/studio space, 15+ therapeutic team including doctors of medicine and naturopathy, and registered nurses.



We are not a concept.
We are a growth
story.

2020 Runway

- Numinus to be listed on TSX-V through RTO in Q1 2020.
- Estimated 2020 revenues from testing/ processing facilities and healing centre: ~\$10M.
- Standard processing/extraction licence by Health Canada expected in Q1 2020.
- Expand our healing centre footprint and brand:
 - Build purpose-built, flagship healing centre in Vancouver.
 - Acquire and integrate 2-4 existing healing centres in Canada aligned with our model.
 - Receive inputs from MAPS and research professionals on space/clinic requirements for trials.
- Amend dealer's licence under the Controlled Substances Act to include MDMA production.
- Analytical testing and extraction to support production of, and research related to, MDMA (LOI signed with PsyGen Labs Inc.).
- Advance therapeutic, evidence-based patient studies in psychedelic therapies (MOU signed with BC Centre on Substance Use).

Backstopped by stable cannabis revenue

Sustainable cannabis revenue driven by our testing and processing laboratory provides us a foundation for growth – differentiating us from others in the psychedelics space.

Our fully built and paid for facility has the capacity to take on THC and CBD product, and is set to be a progressive player in the hemp-derived CBD and cannabis extraction markets upon issuing of its standard processing licence by Health Canada, expected in Q1 2020.



Extraction Capacity

3 billion
mg / year

Capsules

300,000
sellable units / day

Cannabis Tests

100,000
/ year

Estimated Annual Potential Revenue

\$25M
(Year 3)

Leadership Team



PAYTON NYQUEST
Chairman & CEO

Former Director, VP and Head of Sales at Mackie Research Capital, one of Canada's largest independent brokerage firms with a focus on public health and human advancement. Fifteen years experience in investment banking, has raised over \$100 million for 100+ public and private companies. Former investment advisor with Jordan Capital Markets, Canaccord Financial.




MICHAEL TAN
Chief Production Officer

Former/first executive director, BCLDB Cannabis Division. Successfully launched Cannabis operations in BC. Twenty years' strategic planning and execution with national and multinational corporations. High-impact product development, marketing and operations executive with a track record of driving profitable revenue growth.



STACEY WALLIN
Chief Strategy Officer

Founder and CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. She most recently was the Director of Venture Programs at the BC Tech Association with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale stage technology companies.



KRAIG DOCHERTY
Chief Human Resources Officer

Twenty-plus years' experience growing and scaling tech & creative companies such as EA, Activision Blizzard, Indochino, Invoke and Eventbase.



JOHN FONG
Chief Operating Officer

A professional accountant with over two decades of experience in financial and operational management, providing stability and growth solutions for public natural resource companies and technology start-ups.



MING JANG
Chief Financial Officer

Professional accountant with 25 years of senior financial management experience in various sectors, including cannabis and mining. Former financial consultant and CFO for Ignite Brands, Overland Resources, Intigold Mines, and Coventry Resources. Planned and executed in taking several companies public including Coventry Resources and Ignite Brands..

Analytics Team



JUDY VARGA, M.Sc
Head of Laboratory Operations

Analytical chemist with experience in pharmaceutical industry.

GMP/GLP, QC Lead with major Canadian LP for two years.

Advanced microbiology methods



DOROTHEA HANISCH, B.Sc
Head of Regulatory Affairs, QAP

Experience as Health Canada Alternative Qualified Person in Charge (AQPIC).

Licensed pharmacist with a background in pharmaceutical manufacturing.

German experience as an industrial pharmacist, QA/QC, regulatory liaison.



DR KRISTINA GROTZINGER, PhD, B.Sc
Senior Research Scientist

20 years of phytochemistry experience in regulated lab environments.

Health Canada-certified Qualified Person in Charge (QPIC).

SR&ED projects (2013 – present) in analytical methods for cannabis testing.

Avid researcher and lecturer in natural health/herbal medicines and author of peer-reviewed research papers.



DR BERND O. KELLER, PhD
Senior Research Scientist

Over 20 years experience in advanced analytical technologies and methods.

Authored 30 peer reviewed publications.

Former research scientist of Child & Family Research Institute, BC Children's Hospital.

Former director of mass spectrometry facility at Queens University.

Senior Management



LOGAN DIXON
Head of Production

5 years experience in the legal cannabis industry including a large scale global licensed producer.

Experience with various aspects of cultivation, from cloning to curing to extraction and packaging.

Facilitated negotiations of contracts with numerous local economically sustainable and environmentally friendly businesses and First Nations.



ADRIANA BLANCO, LL.M
Corporate Secretary

International legal advisor with 15+ years experience (both government and non-government organizations) in South America, Europe, and North America.

Columbian lawyer licence; currently seeking to qualify in Canada at UBC's LLM CL programme.

Holds a degree in International Law, Human Rights, and Criminal Justice.



TYLER VAUGHAN
Head of Security & IT

Technical services professional with 10+ years of experience.

Former technician with the Canadian Armed Forces.

Experience in operations process creation and management.

Background as an electrician, technician, control centre operator.

Salvation Botanicals⁽¹⁾

Rojo Resources Shares ⁽²⁾	3,599,043
Shares Issued at \$0.32	3,081,170
Shares Issued at \$0.50	18,204,178
Insider/Founder Shares ⁽³⁾	36,982,575
Total Outstanding Shares	61,866,966
Fully Diluted Shares	72,759,055

(1) As of Nov. 1, 2019

(2) Post consolidation of common shares pre-raise

(3) Subject to 36-month escrow schedule

Path to Public

- Definitive arrangement agreement was signed by Salvation Botanicals and Rojo Resources in October 2019
- Salvation acquired Numinus Healing Centre in Q4
- Subject to exchange approval, Salvation to list with the TSX-V through an RTO by Rojo Resources Inc in Q1 and the new company will be marketed as Numinus as of listing



OWEN • BIRD
LAW CORPORATION

& Davidson
Company

Mackie Research
Capital Corporation

MILLER THOMSON
AVOCATS | LAWYERS

N

602 West Hastings Street – Suite 504
Vancouver, BC V6B 1P2

1.855.420.8617

numinus.ca

& salvationbotanicals.ca

